WO2000056336A3 - Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin - Google Patents

Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin Download PDF

Info

Publication number
WO2000056336A3
WO2000056336A3 PCT/EP2000/001940 EP0001940W WO0056336A3 WO 2000056336 A3 WO2000056336 A3 WO 2000056336A3 EP 0001940 W EP0001940 W EP 0001940W WO 0056336 A3 WO0056336 A3 WO 0056336A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyclodextrin
pyrimidine derivative
pharmaceutical compositions
compositions
haemorrhage
Prior art date
Application number
PCT/EP2000/001940
Other languages
French (fr)
Other versions
WO2000056336A2 (en
Inventor
David John Heal
Ian Charles Kilpatrick
Keith Frank Martin
Sharon Lesley Smith
Original Assignee
Knoll Ag
David John Heal
Ian Charles Kilpatrick
Keith Frank Martin
Sharon Lesley Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag, David John Heal, Ian Charles Kilpatrick, Keith Frank Martin, Sharon Lesley Smith filed Critical Knoll Ag
Priority to CA002367040A priority Critical patent/CA2367040A1/en
Priority to EP00910780A priority patent/EP1161243A2/en
Priority to MXPA01009384A priority patent/MXPA01009384A/en
Priority to AU32867/00A priority patent/AU3286700A/en
Priority to JP2000606241A priority patent/JP2002539261A/en
Publication of WO2000056336A2 publication Critical patent/WO2000056336A2/en
Publication of WO2000056336A3 publication Critical patent/WO2000056336A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A pharmaceutical composition comprising a) a 1,2,4-triazolo(1,5-a)pyrimidine derivative of formula (I) including pharmaceutically acceptable salts, racemates, enantiomers, diastereoisomers and mixtures thereof, b) a cyclodextrin. These compositions are useful in the treatment of migraine, seizures and/or neurological disorders such as epilepsy and/or as neuroprotective agents to protect against conditions such as stroke, brain trauma, head injuries and haemorrhage in animals including human beings.
PCT/EP2000/001940 1999-03-18 2000-03-06 Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin WO2000056336A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002367040A CA2367040A1 (en) 1999-03-18 2000-03-06 Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin
EP00910780A EP1161243A2 (en) 1999-03-18 2000-03-06 Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin
MXPA01009384A MXPA01009384A (en) 1999-03-18 2000-03-06 Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin.
AU32867/00A AU3286700A (en) 1999-03-18 2000-03-06 Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin
JP2000606241A JP2002539261A (en) 1999-03-18 2000-03-06 Pharmaceutical composition containing pyrimidine derivative and cyclodextrin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9906126.9A GB9906126D0 (en) 1999-03-18 1999-03-18 Pharmaceutical formulations
GB9906126.9 1999-03-18

Publications (2)

Publication Number Publication Date
WO2000056336A2 WO2000056336A2 (en) 2000-09-28
WO2000056336A3 true WO2000056336A3 (en) 2000-11-16

Family

ID=10849799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/001940 WO2000056336A2 (en) 1999-03-18 2000-03-06 Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin

Country Status (8)

Country Link
EP (1) EP1161243A2 (en)
JP (1) JP2002539261A (en)
CN (1) CN1350456A (en)
AU (1) AU3286700A (en)
CA (1) CA2367040A1 (en)
GB (1) GB9906126D0 (en)
MX (1) MXPA01009384A (en)
WO (1) WO2000056336A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9906130D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Compounds for use in therapy
GB9914743D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
AU2019240286A1 (en) 2018-03-23 2020-11-05 Bast Fibre Technologies Inc. Nonwoven fabric comprised of crimped bast fibers
EP3969639A1 (en) 2019-05-13 2022-03-23 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002767A1 (en) * 1983-12-21 1985-07-04 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
WO1995010521A1 (en) * 1993-10-13 1995-04-20 Knoll Ag Therapeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002767A1 (en) * 1983-12-21 1985-07-04 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
WO1995010521A1 (en) * 1993-10-13 1995-04-20 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
MXPA01009384A (en) 2004-03-19
CA2367040A1 (en) 2000-09-28
EP1161243A2 (en) 2001-12-12
AU3286700A (en) 2000-10-09
WO2000056336A2 (en) 2000-09-28
JP2002539261A (en) 2002-11-19
GB9906126D0 (en) 1999-05-12
CN1350456A (en) 2002-05-22

Similar Documents

Publication Publication Date Title
AU3188097A (en) Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan
WO2005056524A3 (en) Therapeutic agents useful for treating pain
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
CA2316921A1 (en) Aryl fused azapolycyclic compounds
CA2326970A1 (en) Acetylene derivatives as anti-inflammatory/analgesic agents
WO2003053359A3 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
WO2001049281A3 (en) POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES
MY131810A (en) Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
CA2401033A1 (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
CA2343236A1 (en) 4,4-biarylpiperidine derivatives
CA2336909A1 (en) Thiobenzimidazole derivatives which are useful as inhibitors of human chymase activity
MXPA05002420A (en) Thiazole compounds for the treatment of neurodegenerative disorders.
CA2284732A1 (en) Analogs of cocaine
EP2258372B8 (en) A2A antagonists for use in the treatment of motor disorders
AU697679B2 (en) Treatment of tinnitis using neuroprotective agents
NO306509B1 (en) Pyrimidine derivatives, their use and pharmaceutical preparation
CA2173147A1 (en) Anti-obesity agent
EP1666041A3 (en) Xanthine derivatives for treating neurodegenerative disorders
CA2368165A1 (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2002100836A8 (en) Compounds, compositions and methods for modulating beta-amyloid production
WO2006031719A3 (en) 1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00807523.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2367040

Country of ref document: CA

Ref document number: 2367040

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 606241

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/009384

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000910780

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000910780

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09936772

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000910780

Country of ref document: EP